01/28/2026 | Press release | Distributed by Public on 01/28/2026 11:04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
EIKON THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware (State of incorporation or organization) |
84-2807586 (I.R.S. Employer Identification No.) |
|
|
230 Harriet Tubman Way
Millbrae, California (Address of principal executive offices) |
94030 (Zip Code) |
|
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Name of each exchange on which |
|
| Common Stock, par value $0.0001 per share | The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates:
333-292633
Securities to be registered pursuant to Section 12(g) of the Act:
None.
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant's Securities to be Registered.
A description of the common stock, par value $0.0001 per share (the "Common Stock"), of Eikon Therapeutics, Inc., a Delaware corporation (the "Registrant"), to be registered hereunder is contained in the section entitled "Description of Capital Stock" in the prospectus included in the Registrant's Registration Statement on Form S-1 (File No. 333-292633), initially filed with the Securities and Exchange Commission (the "Commission") on January 9, 2026, as amended from time to time (the "Registration Statement"), and is incorporated herein by reference. In addition, a description of the Common Stock will be included in a prospectus to be subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Registration Statement, and such prospectus will be deemed incorporated herein by reference.
Item 2. Exhibits.
Under the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
|
EIKON THERAPEUTICS, INC. |
||||||
|
Date: January 28, 2026 |
By: |
/s/ Roger M. Perlmutter |
||||
|
Roger M. Perlmutter, M.D., Ph.D. Chief Executive Officer |
||||||